The role of GRK6 in animal models of Parkinson's Disease and L-DOPA treatment

Scientific Reports

Volumn 2, Issue , 2012, Pages

  Managò, Francesca ^a   Espinoza, Stefano ^a   Salahpour, Ali ^b   Sotnikova, Tatyana D ^a   Caron, Marc G ^c   Premont, Richard T ^c   Gainetdinov, Raul R ^a,c  

^a ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^b UNIVERSITY OF TORONTO   (Canada)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; G PROTEIN COUPLED RECEPTOR KINASE; G PROTEIN COUPLED RECEPTOR KINASE 6; G-PROTEIN-COUPLED RECEPTOR KINASE 6; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; LEVODOPA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B;

ANIMAL; ARTICLE; C57BL MOUSE; DISEASE MODEL; ENZYMOLOGY; GENETICS; LOCOMOTION; METABOLISM; MOUSE; MOUSE MUTANT; MUTATION; PARKINSON DISEASE; SIGNAL TRANSDUCTION;

ANIMALS; CYCLIC AMP; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; G-PROTEIN-COUPLED RECEPTOR KINASES; GLYCOGEN SYNTHASE KINASE 3; LEVODOPA; LOCOMOTION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTATION; PARKINSON DISEASE; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84859773994     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep00301     Document Type: Article

References (51)

1. Fearnley, J. M. & Lees, A. J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (Pt5), 2283-2301 (1991).
2. Kish, S. J., Shannak, K. & Hornykiewicz, O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 318, 876-880 (1988). (Pubitemid 18090271)
3. Bezard, E., Brotchie, J. M. & Gross, C. E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2, 577-588 (2001). (Pubitemid 33679831)
4. Cotzias, G. C., Papavasiliou, P. S. & Gellene, R. Modification of Parkinsonism-chronic treatment with L-dopa. N Engl J Med 280, 337-345 (1969).
5. Stocchi, F., Nordera, G. & Marsden, C. D. Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Clin Neuropharmacol 20, 95-115 (1997). (Pubitemid 27154837)
6. Beaulieu, J. M. & Gainetdinov, R. R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63, 182-217 (2011).
7. Missale, C., Nash, S. R., Robinson, S. W., Jaber, M. & Caron, M. G. Dopamine receptors: from structure to function. Physiol Rev 78, 189-225 (1998). (Pubitemid 28070979)
8. Ferguson, S. S. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 53, 1-24 (2001). (Pubitemid 32173106)
9. Beaulieu, J. M. et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA 101, 5099-5104 (2004).
10. Lefkowitz, R. J. & Shenoy, S. K. Transduction of receptor signals by beta-arrestins. Science 308, 512-517 (2005).
11. Erdtmann-Vourliotis, M., Mayer, P., Ammon, S., Riechert, U. & Hollt, V. Distribution of G-protein-coupled receptor kinase (GRK) isoforms 2, 3, 5 and 6 mRNA in the rat brain. Brain Res Mol Brain Res 95, 129-137 (2001). (Pubitemid 33000371)
12. Gainetdinov, R. R. et al. Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. Neuron 38, 291-303 (2003). (Pubitemid 36555654)
13. Bezard, E. et al. L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain. Neurobiol Dis 18, 323-335 (2005). (Pubitemid 40431116)
14. Ahmed, M. R., Bychkov, E., Gurevich, V. V., Benovic, J. L. & Gurevich, E. V. Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by l-DOPA treatment. J Neurochem 104, 1622-1636 (2008). (Pubitemid 351316768)
15. Ahmed, M. R. et al. Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease. Sci Transl Med 2, 28ra28 (2010).
16. Aubert, I. et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57, 17-26 (2005). (Pubitemid 40053311)
17. Cenci, M. A., Lee, C. S. & Bjorklund, A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin-and glutamic acid decarboxylase mRNA. Eur J Neurosci 10, 2694-2706 (1998). (Pubitemid 28362576)
18. Sgambato-Faure, V. et al. Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats. J Neuropathol Exp Neurol 64, 936-947 (2005). (Pubitemid 41668923)
19. Gold, S. J. et al. RGS9-2 negatively modulates L-3, 4- dihydroxyphenylalanineinduced dyskinesia in experimental Parkinson's disease. J Neurosci 27, 14338-14348 (2007).
20. Bezard, E. et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 9, 762-767 (2003). (Pubitemid 36749227)
21. Bordet, R. et al. Induction of dopamine D3 receptor expression as amechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA 94, 3363-3367 (1997). (Pubitemid 27157317)
22. Bychkov, E., Ahmed, M. R., Dalby, K. N. & Gurevich, E. V. Dopamine depletion and subsequent treatmentwith L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum. J Neurochem 102, 699-711 (2007). (Pubitemid 47057295)
23. Boulay, D. et al. Haloperidol-induced catalepsy is absent in dopamine D(2), but maintained in dopamine D(3) receptor knock-outmice. Eur J Pharmacol 391, 63-73 (2000). (Pubitemid 30138081)
24. Beaulieu, J. M. et al. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122, 261-273 (2005).
25. Emamian, E. S., Hall, D., Birnbaum, M. J., Karayiorgou, M. & Gogos, J. A. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36, 131-137 (2004). (Pubitemid 38174370)
26. Sotnikova, T. D. et al. Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease. PLoS Biol 3, e271 (2005).
27. Gainetdinov, R. R. & Caron, M. G. Monoamine transporters: from genes to behavior. Annu Rev Pharmacol Toxicol 43, 261-284 (2003). (Pubitemid 37372642)
28. Giros, B., Jaber, M., Jones, S. R., Wightman, R. M. & Caron, M. G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606-612 (1996). (Pubitemid 26052818)
29. Costa, R. M. et al. Rapid alterations in corticostriatal ensemble coordination during acute dopamine-dependent motor dysfunction. Neuron 52, 359-369 (2006). (Pubitemid 44548339)
30. Lundblad, M., Picconi, B., Lindgren, H. & Cenci, M. A. A model of L-DOPAinduced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 16, 110-123 (2004). (Pubitemid 38569802)
31. Winkler, C., Kirik, D., Bjorklund, A. & Cenci, M. A. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 10, 165-186 (2002). (Pubitemid 34775470)
32. Santini, E. et al. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 27, 6995-7005 (2007). (Pubitemid 47015907)
33. Masri, B. et al. Antagonism of dopamineD2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci USA 105, 13656-13661 (2008).
34. Barak, L. S. et al. Pharmacological characterization of membrane-expressed human trace amine-associated receptor 1 (TAAR1) by a bioluminescence resonance energy transfer cAMP biosensor. Mol Pharmacol 74, 585-594 (2008).
35. Klewe, I. V. et al. Recruitment of beta-arrestin2 to the dopamine D2 receptor: insights into anti-psychotic and anti-parkinsonian drug receptor signaling. Neuropharmacology 54, 1215-1222 (2008).
36. Allen, J. A. et al. Discovery of {beta}-Arrestin-Biased Dopamine D2 Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy. Proc Natl Acad Sci USA 108, 18488-18493 (2011).
37. Gainetdinov, R. R., Premont, R. T., Bohn, L. M., Lefkowitz, R. J. & Caron, M. G. Desensitization ofGprotein-coupled receptors and neuronal functions. Annu Rev Neurosci 27, 107-144 (2004). (Pubitemid 39050399)
38. Premont, R. T. & Gainetdinov, R. R. Physiological roles of G protein-coupled receptor kinases and arrestins. Annu Rev Physiol 69, 511-534 (2007). (Pubitemid 46457653)
39. Luttrell, L. M. & Lefkowitz, R. J. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 115, 455-465 (2002). (Pubitemid 34182973)
40. Kim, J. et al. Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling. Proc Natl Acad Sci USA 102, 1442-1447 (2005). (Pubitemid 40209189)
41. Rajagopal, K. et al. Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci USA 103, 16284-16289 (2006). (Pubitemid 44715188)
42. Ren, X. R. et al. Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor. Proc Natl Acad Sci USA 102, 1448-1453 (2005).
43. Ghisi, V. et al. Reduced D2-mediated signaling activity and trans-synaptic upregulation of D1 and D2 dopamine receptors in mice overexpressing the dopamine transporter. Cell Signal 21, 87-94 (2009).
44. Ungerstedt, U. & Arbuthnott, G. W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24, 485-493 (1970).
45. Gerfen, C. R., Miyachi, S., Paletzki, R. & Brown, P. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci 22, 5042-5054 (2002). (Pubitemid 37465618)
46. Kim, D. S., Palmiter, R. D., Cummins, A. & Gerfen, C. R. Reversal of supersensitive striatal dopamine D1 receptor signaling and extracellular signal-regulated kinase activity in dopamine-deficient mice. Neuroscience 137, 1381-1388 (2006). (Pubitemid 43133161)
47. Pavon, N., Martin, A. B., Mendialdua, A. & Moratalla, R. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry 59, 64-74 (2006). (Pubitemid 43005237)
48. Santini, E. et al. L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem 108, 621-633 (2009).
49. Santini, E., Valjent, E. & Fisone, G. Parkinson's disease: levodopa-induced dyskinesia and signal transduction. FEBS J 275, 1392-1399 (2008). (Pubitemid 351388785)
50. Franklin, K. B. J. & Paxinos, G. The mouse brain in stereotaxic coordinates. (Academic Press, 1997).
51. Cenci, M. A. & Lundblad, M. Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr Protoc Neurosci Chapter 9, Unit 9 25 (2007).